microdosing tirzepatide for autoimmune is an emerging approach supporting metabolic and hormonal health. By using smaller, carefully titrated doses, some patients may experience improved insulin sensitivity, reduced inflammation, and better metabolic regulation. For Microdosing Tirzepatide and Semaglutide for

Trajectories of percentage BMI change during the 12 months after semaglutide initiation stratified by (A) semaglutide dose, (B) sex, (C) type 2 diabetes status, and (D) baseline BMI

Interestingly, the opioid antagonist naloxone can block some of DSIPs effects, confirming this opioid system involvement

Weeks 5 to 8 (maintenance phase): Structural tissue changes become more apparent

End goal: A healthier pregnancy While semaglutides carry potential risks during pregnancy, Kumar emphasized that when prescribed properly to a woman who is struggling with her metabolic health, these medications could help enable a healthier pregnancy

- LHA- + , , , ,